AntiRadical Therapeutics

Executive Summary

AntiRadical Therapeutics is a pre-clinical biotech company headquartered in Cambridge, MA, focused on developing novel biologics to combat aging and age-related diseases. The company’s lead candidate, SE3TPL, targets fundamental mechanisms of aging such as oxidative stress and chronic inflammation, with initial applications in neurodegenerative disorders. Founded in 2020, the company operates in stealth mode with limited public disclosures, but its scientific premise aligns with the growing anti-aging therapeutic landscape. Given the early stage, the company’s progress hinges on advancing SE3TPL through preclinical development and securing funding. The platform’s potential to address multiple age-related conditions offers significant upside if validated, though substantial execution risks remain typical for pre-clinical stage companies. The conviction score reflects the early-stage nature, modest public information, and the high attrition rate in anti-aging drug development.

Upcoming Catalysts (preview)

• Q3 2026Initiation of IND-enabling studies40% success
• Q2 2026Series A funding round announcement50% success
• Q4 2026Preclinical efficacy data release in a peer-reviewed journal30% success